SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

1. Name and Address of Reporting Person

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

	OMB Number:	3235-0287								
	Estimated average burden hours per response: 0.5									
l	hours per response:	0.5								

5. Relationship of Reporting Person(s) to Issuer

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading Symbol

LILLY E	NDOWMENT	ELI LILLY &	Co	LLY]	(Chec	Director	X 10% C	Dwner						
(Last)	(First)	3. Date of Earliest Tr 01/31/2024	ransacti	on (Mo	onth/Day/Yea		Officer (give title below)	Other below	(specify)						
2801 NOR	TH MERIDIAN ST	FREET	4. If Amendment, Da	ate of Or	riginal	Filed (Month/	ar) 6. Indi Line)	vidual or Joint/Group Filing (Check Applicable							
(Street)							X	Form filed by On	Form filed by One Reporting Person						
INDIANA	POLIS IN	46208-0068						Form filed by More than One Reporting Person							
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication												
		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Table I - Non-Derivat	ive Securities A	Acquir	ed, I	Disposed	of, or	Beneficially	/ Owned						
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year	r) 2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of	a Acquire f (D) (Inst	ed (A) or tr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
				Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)						
Common S	tock	01/31/2024		S		35,506	D	\$ 645.282 ⁽¹⁾	99,376,877	D					
Common S	tock	01/31/2024		S		9,169	D	\$ 646.41 ⁽²⁾	99,367,708	D					
Common S	tock	01/31/2024		S		8,696	D	\$647.532 ⁽³⁾	99,359,012	D					
Common S	tock	01/31/2024		S		7,424	D	\$ 648.598 ⁽⁴⁾	99,351,588	D					
Common S	tock	01/31/2024		S		4,931	D	\$649.803(5)	99,346,657	D					
Common S	tock	01/31/2024		S		815	D	\$650.729(6)	99,345,842	D					
Common S	tock	01/31/2024		S		900	D	\$ 651. 5 6 ⁽⁷⁾	99,344,942	D					
Common S	tock	01/31/2024		S		1,900	D	\$654.252(8)	99,343,042	D					
Common S	tock	01/31/2024		S		2,750	D	\$655.265 ⁽⁹⁾	99,340,292	D					
Common S	tock	01/31/2024		S		1,700	D	\$656.302(10)	99,338,592	D					
Common S	tock	01/31/2024		S		600	D	\$657.398(11)	99,337,992	D					
Common S	tock	01/31/2024		S		1,700	D	\$658.651(12)	99,336,292	D					
Common S	tock	01/31/2024		S		797	D	\$ 659.64 ⁽¹³⁾	99,335,495	D					
Common S	tock	01/31/2024		S		985	D	\$661.088(14)	99,334,510	D					
Common S	tock	01/31/2024		S		200	D	\$661.63	99,334,310	D					
Common S	tock	01/31/2024		S		500	D	\$662.808(15)	99,333,810	D					

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)		Transaction Code (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	t
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 645.00 to 645.95, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), and (15) to this Form 4.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$646.00 to \$646.99, inclusive.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$647.07 to \$648.0202, inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$648.115 to \$649.11, inclusive.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$649.185 to \$650.00, inclusive.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$650.235 to \$651.00, inclusive.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$651.3174 to \$651.83, inclusive.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$653.765 to \$654.76, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$654.765 to \$655.60, inclusive.

10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$655.86 to \$656.635, inclusive.

11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$656.98 to \$657.87, inclusive.

12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$658.11 to \$658.94, inclusive.

13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$659.185 to \$660.0675, inclusive.

14. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$660.5246 to \$661.23, inclusive.

15. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$662.65 to \$663.025, inclusive.

/s/ Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment Inc. ** Signature of Reporting Person

02/01/2024

n Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.